All data are based on the daily closing price as of April 1, 2025
l

Lumosa Therapeutics

6535.TWO
5.21 USD
-0.15
-2.80%

Overview

Last close
5.21 usd
Market cap
859.65M usd
52 week high
12.06 usd
52 week low
1.82 usd
Target price
6.93 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
746.263
Price/Book Value
15.7264
Enterprise Value
865.04M usd
EV/Revenue
733.4959
EV/EBITDA
N/A

Key financials

Revenue TTM
1.18M usd
Gross Profit TTM
533524.1 usd
EBITDA TTM
-10.63M usd
Earnings per Share
-0.08 usd
Dividend
N/A usd
Total assets
49.09M usd
Net debt
-8.59M usd

About

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT " 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
  • Symbol
    6535.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Rong-Jin Lin Ph.D.
  • Headquarter
    Taipei
  • Web site
    https://www.lumosa.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top